Navigation Links
Alere Inc. Announces Early Results of its Tender Offer and Consent Solicitation for Any and All of its 7.875% Senior Notes due 2016
Date:12/11/2012

WALTHAM, Mass., Dec. 11, 2012 /PRNewswire/ -- Alere Inc. (NYSE: ALR) (the "Company") announced today the early results of its previously announced cash tender offer and consent solicitation with respect to its outstanding $250.0 million aggregate principal amount of 7.875% Senior Notes due 2016 (the "Notes") (CUSIP No: 46126P AG1).

As of 5:00 p.m., New York City time, on December 10, 2012 (the "Consent Payment Deadline"), the tender agent had received valid tenders and related consents from holders ("Holders") of $248,145,000 of the outstanding aggregate principal amount of Notes, or approximately 99.3% of such Notes, all of which have been accepted for purchase.  The consents received exceeded the number needed to approve the proposed amendments to the indenture dated as of August 11, 2009 among the Company, The Bank of New York Mellon Trust Company, N.A. (the "Trustee") and certain guarantors named therein (as amended, supplemented or otherwise modified prior to the date hereof, the "Indenture"), under which the Notes were issued.

The tender offer is subject to the terms and conditions set forth in the Offer to Purchase and Consent Solicitation Statement dated November 27, 2012 (the "Offer to Purchase").  The tender offer will expire at 11:59 p.m., New York City time, on December 26, 2012 unless extended or earlier terminated (such time and date, as the same may be extended, the "Expiration Date").

The parties to the Indenture have executed a fourteenth supplemental indenture (the "Fourteenth Supplemental Indenture") to the Indenture, which, among other modifications, has eliminated substantially all of the restrictive covenants and certain events of default applicable to the Notes.

Holders who tendered their Notes and thereby provided their consents to the proposed amendments to the Indenture on or before the Consent Payment Deadline will receive the Total Consideration (as defined below).  Holders of Notes who tendered or tender their Notes after the Consent Payment Deadline and on or before the Expiration Date will only receive the Tender Offer Consideration (as defined below).

The "Total Consideration" for each $1,000.00 principal amount of Notes validly tendered, and not validly withdrawn, prior to the Consent Payment Deadline and accepted for purchase is $1,049.43. The "Tender Offer Consideration" for each $1,000 principal amount of Notes validly tendered, and not validly withdrawn, after the Consent Payment Deadline but prior to the Expiration Date and accepted for purchase is $1,019.43.  The Tender Offer Consideration is the Total Consideration minus the Consent Payment (as defined below).  Holders who validly tendered or tender, and did not and do not validly withdraw, Notes that have been or are accepted for purchase by the Company will also receive accrued and unpaid interest from the most recent interest payment date for the Notes to, but not including, the applicable payment date.

The "Consent Payment" is an amount equal to $30.00 per $1,000.00 principal amount of Notes and is payable only with respect to each Note that was validly tendered, and not validly withdrawn, on or before the Consent Payment Deadline and accepted for purchase.  The Consent Payment is included in the calculation of the Total Consideration and is not in addition to the Total Consideration.

Any Notes not tendered and purchased pursuant to the tender offer will remain outstanding after the expiration of the tender offer, and the holders will be subject to the terms of the Indenture, as amended by the Fourteenth Supplemental Indenture, even though they did not consent to the amendments.

The Company has engaged Jefferies & Company, Inc. as Dealer Manager and Solicitation Agent for the tender offer and consent solicitation. Persons with questions regarding the tender offer and consent solicitation should contact Jefferies & Company, Inc. at (888) 708-5831 (toll-free) or (203) 708-5831 (collect).  Requests for documents should be directed to i-Deal LLC, the Tender Agent and Information Agent for the tender offer and consent solicitation, at (212) 849-5000 (brokers and bankers) or (888) 593-9546 (all others).

This press release is for information purposes only and is not an offer to purchase, a solicitation of acceptance of the offer to purchase or a solicitation of a consent with respect to any of the Notes.  The tender offer and consent solicitation are being made only pursuant to the tender offer and consent solicitation documents, including the Offer to Purchase, which the Company has distributed to Holders.  The tender offer and consent solicitation are not being made to Holders in any jurisdiction in which the making or acceptance thereof would not be in compliance with the securities, blue sky or other laws of such jurisdiction.

About Alere Inc.

By developing new capabilities in near-patient diagnosis, monitoring and health management, Alere enables individuals to take charge of improving their health and quality of life at home.  Alere's global leading products and services, as well as its new product development efforts, focus on cardiology, women's health, infectious disease, oncology and toxicology.  Alere is headquartered in Waltham, Massachusetts.


'/>"/>
SOURCE Alere Inc.
Copyright©2012 PR Newswire.
All rights reserved

Related medicine technology :

1. Alere Inc. Announces Offering of $450 Million of Senior Notes
2. Precision Optics Corporation Announces $1 Million Order for Microprecision™ Based Endoscopes
3. Young Innovations, Inc. Announces Record Sales and EPS for the Quarter Ended March 31, 2012
4. JDRF Announces Research Collaboration with Dexcom, Inc. to Develop "Smart Transmitter" Technology to Accelerate Artificial Pancreas Studies
5. Misonix Announces New Distribution Agreement For Panama
6. University of Maryland BioPark Announces MedImmunes Dr. Bahija Jallal as Newest Member of Board of Directors for UM Health Sciences Research Park
7. Novelos Therapeutics Announces Successful Completion of First Cohort In Lung Cancer Trial With I-124-CLR1404 (LIGHT) Cancer-Targeted PET Imaging Agent at UW Carbone Cancer Center
8. Boston Scientific Announces CE Mark and European Launch of Emerge™ PTCA Dilatation Catheter
9. Soligenix Announces Further Progress with ThermoVax™ for Long-Term Vaccine ThermoStability
10. Masimo Announces New Low-Profile Infant and Neonatal Pulse Oximetry Sensors
11. Anthera Announces the Completion of Patient Dosing in Phase 2b PEARL-SC Study
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:3/29/2017)... 2017  The leader in accelerated orthodontics, OrthoAccel ® ... Daher , Manal Ibrahim , Kenji Ojima ... be the featured microlecture presenters at the AcceleDent ® ... Orthodontists (AAO) Annual Session, April 21-25, 2017. Orthodontists and ... daily at 11:20 a.m. On the opening morning of ...
(Date:3/29/2017)... , March 29, 2017  Glenmark Pharmaceuticals, ... for GSP 301, an investigational fixed-dose combination of ... mcg) administered twice-daily as a nasal spray being ... These results are from a recently completed Phase ... GSP 301 combination therapy versus mometasone, olopatadine or ...
(Date:3/29/2017)... 29, 2017 Transparency Market ... provides an exhaustive study of the U.S. substance abuse ... companies are functional in this market at present, ... leading companies, such as GlaxoSmithKline Plc., Pfizer Inc., ... on various marketing strategies to increase their visibility, ...
Breaking Medicine Technology:
(Date:3/29/2017)... ... ... Brand EXOUS Bodygear announced today a special sale price for the EX-701 Knee ... the price will be only $19.97. The EXOUS Bodygear 65cm exercise ball ... $19.97). , The special promotional prices are to help individuals get their products at ...
(Date:3/29/2017)... ... March 29, 2017 , ... Based ... into the challenges employers face in trying to balance both short-term and long-term ... programs? Adding to the growing complexity, companies are finding that the short-term ...
(Date:3/29/2017)... , ... March 29, 2017 , ... ... buildings (MOBs) and other outpatient facilities, and who are the most active developers? ... those questions, Revista and Healthcare Real Estate Insights (HREI) found that outpatient medical ...
(Date:3/29/2017)... ... March 29, 2017 , ... HealthCareMandA.com will host an ... 20, 2017, at 1:00 PM ET. A recording of the webinar will also be ... Series. , Home health and hospice companies are still popular targets for healthcare investors. ...
(Date:3/29/2017)... ... March 29, 2017 , ... ... now have easier access to the robotic-assisted total-hip and partial-knee replacement surgeries ... Orthopaedic surgeons at Forbes Hospital and Jefferson Hospital recently started performing these ...
Breaking Medicine News(10 mins):